Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19(+) CD33(+) leukemia cells

Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune escape. The combination of B lymphoid marker CD19 and myeloid marker CD33 is exclusively present on biphenotypic B/myeloid leukemia cells. Tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Roskopf, Claudia C., Braciak, Todd A., Fenn, Nadja C., Kobold, Sebastian, Fey, Georg H., Hopfner, Karl-Peter, Oduncu, Fuat S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008383/
https://www.ncbi.nlm.nih.gov/pubmed/26981773
http://dx.doi.org/10.18632/oncotarget.8022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008383/
https://www.ncbi.nlm.nih.gov/pubmed/26981773
http://dx.doi.org/10.18632/oncotarget.8022

Ejemplares similares